Literature DB >> 24568285

Prescription practices for chronic obstructive pulmonary disease: findings from the national ambulatory medical care survey 1999-2010.

Earl S Ford1, David M Mannino, Wayne H Giles, Anne G Wheaton, Yong Liu, Janet B Croft.   

Abstract

Recent trends in prescriptions for medicines used to treat chronic obstructive pulmonary disease (COPD) in the United States have received little attention. Our objective was to examine trends in prescribing practices for medications used to treat COPD. We examined data from surveys of national samples of office visits to non-federal employed office-based physicians in the United States by patients aged ≥40 years with COPD recorded by the National Ambulatory Medical Care Survey from 1999 to 2010. From three diagnostic codes, office visits by patients with COPD were identified. Prescribed medications were identified from up to 8 recorded medications. The percentage of these visits during which a prescription for any medication used to treat COPD was issued increased from 27.0% in 1999 to 49.1% in 2010 (p trend < 0.001). Strong increases were noted for short-acting beta-2 agonists (17.6% in 1999 to 24.7% in 2010; p trend < 0.001), long-acting beta-2 agonists as single agents or combination products (6.2% in 1999 to 28.3% in 2010; p trend < 0.001), inhaled corticosteroids as single agents or combination products (10.9% in 1999 to 30.9% in 2010; p trend < 0.001), and tiotropium (3.8% in 2004 to 17.2% in 2010; p trend < 0.001). Since 1999, prescription patterns for medicines used to treat COPD have changed profoundly in the United States.

Entities:  

Keywords:  COPD; prescriptions; therapeutics; trends

Mesh:

Substances:

Year:  2014        PMID: 24568285      PMCID: PMC4559259          DOI: 10.3109/15412555.2013.840570

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  13 in total

Review 1.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

Review 2.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1995-11       Impact factor: 21.405

3.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

Authors:  Peter M A Calverley; Julie A Anderson; Bartolome Celli; Gary T Ferguson; Christine Jenkins; Paul W Jones; Julie C Yates; Jørgen Vestbo
Journal:  N Engl J Med       Date:  2007-02-22       Impact factor: 91.245

Review 4.  The epidemiology and economics of chronic obstructive pulmonary disease.

Authors:  David M Mannino; Sidney Braman
Journal:  Proc Am Thorac Soc       Date:  2007-10-01

5.  Sex differences in ambulatory visits for chronic obstructive pulmonary disease, based on the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey from 1995 to 2004.

Authors:  Dong-Churl Suh; Helen Lau; Shibani M Pokras; In-Sun Choi; Elmira Valiyeva
Journal:  Respir Care       Date:  2008-11       Impact factor: 2.258

6.  The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.

Authors:  Jadwiga A Wedzicha; Peter M A Calverley; Terence A Seemungal; Gerry Hagan; Zainab Ansari; Robert A Stockley
Journal:  Am J Respir Crit Care Med       Date:  2007-10-04       Impact factor: 21.405

7.  Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians.

Authors:  Amir Qaseem; Vincenza Snow; Paul Shekelle; Katherine Sherif; Timothy J Wilt; Steven Weinberger; Douglas K Owens
Journal:  Ann Intern Med       Date:  2007-11-06       Impact factor: 25.391

8.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Authors:  Donald P Tashkin; Bartolome Celli; Stephen Senn; Deborah Burkhart; Steven Kesten; Shailendra Menjoge; Marc Decramer
Journal:  N Engl J Med       Date:  2008-10-05       Impact factor: 91.245

Review 9.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

Authors:  Klaus F Rabe; Suzanne Hurd; Antonio Anzueto; Peter J Barnes; Sonia A Buist; Peter Calverley; Yoshinosuke Fukuchi; Christine Jenkins; Roberto Rodriguez-Roisin; Chris van Weel; Jan Zielinski
Journal:  Am J Respir Crit Care Med       Date:  2007-05-16       Impact factor: 21.405

10.  Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease.

Authors:  Bartolome Celli; Marc Decramer; Steven Kesten; Dacheng Liu; Sunil Mehra; Donald P Tashkin
Journal:  Am J Respir Crit Care Med       Date:  2009-09-03       Impact factor: 21.405

View more
  10 in total

1.  Non-health Care Facility Medication Errors Associated with Hormones and Hormone Antagonists in the United States.

Authors:  Pranav Magal; Henry A Spiller; Marcel J Casavant; Thitphalak Chounthirath; Nichole L Hodges; Gary A Smith
Journal:  J Med Toxicol       Date:  2017-09-13

2.  Prescribing Pathways to Triple Therapy: A Retrospective Observational Study of Adults with Chronic Obstructive Pulmonary Disease in the UK.

Authors:  Jennifer K Quint; Alessandra Venerus; Caroline O'Leary; Melissa Myland; Ulf Holmgren; Precil Varghese; Claudia Cabrera
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-12-08

3.  Pulmonary Rehabilitation Utilization in Older Adults With Chronic Obstructive Pulmonary Disease, 2003 to 2012.

Authors:  Shawn P E Nishi; Wei Zhang; Yong-Fang Kuo; Gulshan Sharma
Journal:  J Cardiopulm Rehabil Prev       Date:  2016 Sep-Oct       Impact factor: 2.081

4.  Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Treated with Nebulized Arformoterol Following a Respiratory Event.

Authors:  Maryam Navaie; Bartolome R Celli; Zhun Xu; Soojin Cho-Reyes; Carole Dembek; Todd P Gilmer
Journal:  Chronic Obstr Pulm Dis       Date:  2019-10-23

5.  Real-life GOLD 2011 implementation: the management of COPD lacks correct classification and adequate treatment.

Authors:  Vladimir Koblizek; Ladislav Pecen; Jaromir Zatloukal; Jana Kocianova; Marek Plutinsky; Vitezslav Kolek; Barbora Novotna; Eva Kocova; Sarka Pracharova; Ales Tichopad
Journal:  PLoS One       Date:  2014-11-07       Impact factor: 3.240

6.  The efficacy and safety of inhaled corticosteroids: are we ignoring the potential advantages of ciclesonide?

Authors:  Thys van der Molen; Janwillem W H Kocks
Journal:  NPJ Prim Care Respir Med       Date:  2014-05-20       Impact factor: 2.871

7.  An evaluation of early medication use for COPD: a population-based cohort study.

Authors:  Jamie Falk; Natalia Dik; Shawn Bugden
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-12-07

8.  Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment.

Authors:  Bartolome R Celli; Maryam Navaie; Zhun Xu; Soojin Cho-Reyes; Carole Dembek; Todd P Gilmer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-05-15

9.  Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada.

Authors:  Hamid Tavakoli; Kate M Johnson; J Mark FitzGerald; Don D Sin; Andrea S Gershon; Tetyana Kendzerska; Mohsen Sadatsafavi
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-09-03

10.  Temporal Trends Of Pharmacologic Therapies For Patients With Chronic Obstructive Pulmonary Disease In Alberta, Canada.

Authors:  Dat T Tran; Ilke Akpinar; Irvin Mayers; Tatiana Makhinova; Philip Jacobs
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-09-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.